AFT Pharmaceuticals (ASX:AFP, NZE:AFT) expanded its US licensing agreement with supplier Hikma Pharmaceuticals to include its pain relief medicine Combogesic Rapid, according to a Monday filing with the New Zealand bourse.

Under the deal, Hikma will take over all channels for Combogesic Rapid in the US, the filing said. The companies will also restructure the profit-sharing arrangements for Combogesic IV and tablets to quarterly payments.